Neoadjuvant chemotherapy for bladder cancer: the pros and cons
https://doi.org/10.17650/1726-9776-2006-2-2-31-34
Abstract
In the past 15 years, the results of studies on neoadjuvant chemotherapy have been contradictory. The 2005 meta-analysis pooled data on 3005 patients with bladder cancer. The results of the analysis show an absolute increase in survival by 5% over 5 years when neoadjuvant chemotherapy was used in combination with cisplatin in patients with T2-T4aN0 bladder cancer. These data are of clinical significance for patients with Stage 0-1 bladder cancer and creatinine clearance >50 ml/min and in those aged under 70 years.
With neoadjuvant chemotherapy used in combination with transurethral resection and radiation teletherapy, 5-survival rates are about 50%. Neoadjuvant chemotherapy with platinum agents should be used in multimodality treatment for invasive bladder cancer.
About the Authors
O. B. Karyakin
Medical Radiology Research Center, Russian Academy of Medical Sciences
Russian Federation
Obninsk
Russian Federation
Obninsk
A. M. Popov
Medical Radiology Research Center, Russian Academy of Medical Sciences
Russian Federation
Obninsk
Russian Federation
Obninsk
References
1. Bassi P., Ferrante G.D., Piazza N. et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999;161(5):1494–7.
2. Аксель Е.М. Заболеваемость злокачественными новообразованиями мочевых и мужских половых органов в России. Онкоурология 2005;1: 3–6.
3. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48 (2):202–5.
4. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. The Lancet 2003;361:1927–34.
5. Pectasides D., Pectasides M., Nikolaou M. et al. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Eur Urol 2005;48(1):60–7.
6. Sternberg C.N., Pansadoro V., Calabro F. et al. Neoadjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol 1999;11: 1301–5.
7. Herr H.W., Bajorin D.F., Scher H.I. et al. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998;16: 1298–301.
8. Матвеев Б.П., Фигурин К.М., Токтомушев А.Т. Результаты органосохраняющей терапии инвазивного рака мочевого пузыря. Урология 2002;3: 3–5.
9. Cervek J. et al. Invasive bladder cancer: our experience with bladder sparing approach. Int J Rad Oncol Biol Phis 1998;41(2): 273–8.
10. Arias F., Dominguerz M.A., Martinez E. et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Rad Oncol Biol Phis 2000; 47 (2):373–8.
11. Kachnic L.A., Kaufman D.S., Heney N.M. et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997;15: 1022–9.
12. Shipley W.U., Winter K.A., Kaufman D.S. et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16 (11): 3576–83.
Review
For citations:
Karyakin O.B., Popov A.M. Neoadjuvant chemotherapy for bladder cancer: the pros and cons. Cancer Urology. 2006;2(2):31-34. (In Russ.) https://doi.org/10.17650/1726-9776-2006-2-2-31-34
Views:
384
Email this article 